Skip to main content

Articles

Page 3 of 18

  1. The Centiloid scale was developed to standardise the results of beta-amyloid (Aβ) PET. We aimed to determine the Centiloid unit (CL) thresholds for CERAD sparse and moderate-density neuritic plaques, Alzheimer...

    Authors: Sanka Amadoru, Vincent Doré, Catriona A. McLean, Fairlie Hinton, Claire E. Shepherd, Glenda M. Halliday, Cristian E. Leyton, Paul A. Yates, John R. Hodges, Colin L. Masters, Victor L. Villemagne and Christopher C. Rowe

    Citation: Alzheimer's Research & Therapy 2020 12:22

    Content type: Research

    Published on:

  2. Synapse damage and loss are fundamental to the pathophysiology of Alzheimer’s disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical d...

    Authors: Martí Colom-Cadena, Tara Spires-Jones, Henrik Zetterberg, Kaj Blennow, Anthony Caggiano, Steven T. DeKosky, Howard Fillit, John E. Harrison, Lon S. Schneider, Phillip Scheltens, Willem de Haan, Michael Grundman, Christopher H. van Dyck, Nicholas J. Izzo and Susan M. Catalano

    Citation: Alzheimer's Research & Therapy 2020 12:21

    Content type: Review

    Published on:

  3. Until relatively recently, a diagnosis of probable Alzheimer’s disease (AD) and other neurodegenerative disorders was principally based on clinical presentation, with post-mortem examination remaining a gold s...

    Authors: Pawel Obrocki, Ayesha Khatun, Deborah Ness, Konstantin Senkevich, Jörg Hanrieder, Federica Capraro, Niklas Mattsson, Ulf Andreasson, Erik Portelius, Nicholas J. Ashton, Kaj Blennow, Michael Schöll, Ross W. Paterson, Jonathan M. Schott and Henrik Zetterberg

    Citation: Alzheimer's Research & Therapy 2020 12:20

    Content type: Review

    Published on:

  4. The human APOE gene, which codes for apolipoprotein E (apoE), has three major polymorphic alleles: ε2, ε3, and ε4 that give rise to amino acid substitutions. APOE-ε4 is a strong risk factor of sporadic Alzheimer’...

    Authors: K. Minta, G. Brinkmalm, S. Janelidze, S. Sjödin, E. Portelius, E. Stomrud, H. Zetterberg, K. Blennow, O. Hansson and U. Andreasson

    Citation: Alzheimer's Research & Therapy 2020 12:19

    Content type: Research

    Published on:

  5. Biomarkers are increasingly employed for effective research into neurodegenerative diseases. They have become essential for reaching an accurate clinical diagnosis, monitoring disease, and refining entry crite...

    Authors: Ayesha Khatun, Ross W. Paterson and Michael Schöll

    Citation: Alzheimer's Research & Therapy 2020 12:18

    Content type: Review

    Published on:

  6. Crenezumab, a fully humanized anti-beta-amyloid (Aβ) immunoglobulin G4 (IgG4) monoclonal antibody, binds to both monomeric and aggregated forms of Aβ. We assessed the pharmacokinetics (PK)/pharmacodynamics (PD...

    Authors: Kenta Yoshida, Anita Moein, Tobias Bittner, Susanne Ostrowitzki, Helen Lin, Lee Honigberg, Jin Y. Jin and Angelica Quartino

    Citation: Alzheimer's Research & Therapy 2020 12:16

    Content type: Research

    Published on:

  7. Metabotropic glutamate subtype 5 receptors (mGluR5) modulate synaptic transmission and may constitute an important therapeutic target in Alzheimer’s disease (AD) by mediating the synaptotoxic action of amyloid...

    Authors: Adam P. Mecca, Julia W. McDonald, Hannah R. Michalak, Tyler A. Godek, Joanna E. Harris, Erika A. Pugh, Emily C. Kemp, Ming-Kai Chen, Arash Salardini, Nabeel B. Nabulsi, Keunpoong Lim, Yiyun Huang, Richard E. Carson, Stephen M. Strittmatter and Christopher H. van Dyck

    Citation: Alzheimer's Research & Therapy 2020 12:15

    Content type: Research

    Published on:

  8. Although structural and functional changes of the striatum and hippocampus are present in familial Alzheimer’s disease, little is known about the effects of specific gene mutation or disease progression on the...

    Authors: Meina Quan, Tan Zhao, Yi Tang, Ping Luo, Wei Wang, Qi Qin, Tingting Li, Qigeng Wang, Jiliang Fang and Jianping Jia

    Citation: Alzheimer's Research & Therapy 2020 12:14

    Content type: Research

    Published on:

  9. Mounting evidence points to a crucial role of amyloid-β (Aβ) in the pathophysiology of Alzheimer’s disease (AD), a disorder in which brain glucose hypometabolism, downregulation of central elements of phosphor...

    Authors: Krystal Sotolongo, Jorge Ghiso and Agueda Rostagno

    Citation: Alzheimer's Research & Therapy 2020 12:13

    Content type: Research

    Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2020 12:32

  10. Pyroglutamate-3 Aβ (pGlu-3 Aβ) is an N-terminally truncated and post-translationally modified Aβ species found in Alzheimer’s disease (AD) brain. Its increased peptide aggregation propensity and toxicity make ...

    Authors: Helen Crehan, Bin Liu, Martin Kleinschmidt, Jens-Ulrich Rahfeld, Kevin X. Le, Barbara J. Caldarone, Jeffrey L. Frost, Thore Hettmann, Birgit Hutter-Paier, Brian O’Nuallain, Mi-Ae Park, Marcelo F. DiCarli, Inge Lues, Stephan Schilling and Cynthia A. Lemere

    Citation: Alzheimer's Research & Therapy 2020 12:12

    Content type: Research

    Published on:

  11. Evidence from previous studies suggests that bilingualism contributes to cognitive reserve because bilinguals manifest the first symptoms of Alzheimer’s disease (AD) up to 5 years later than monolinguals. Othe...

    Authors: Víctor Costumero, Lidon Marin-Marin, Marco Calabria, Vicente Belloch, Joaquín Escudero, Miguel Baquero, Mireia Hernandez, Juan Ruiz de Miras, Albert Costa, Maria-Antònia Parcet and César Ávila

    Citation: Alzheimer's Research & Therapy 2020 12:11

    Content type: Research

    Published on:

  12. To date, no symptomatic treatment is available for patients with vascular cognitive impairment (VCI). In the proof-of-principle study Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI), we inv...

    Authors: Jolien F. Leijenaar, Geert Jan Groeneveld, Erica S. Klaassen, Anna E. Leeuwis, Philip Scheltens, Henry C. Weinstein, Joop M. A. van Gerven, Frederik Barkhof, Wiesje M. van der Flier and Niels D. Prins

    Citation: Alzheimer's Research & Therapy 2020 12:10

    Content type: Research

    Published on:

  13. Mounting evidence links poor sleep quality with a higher risk of late-life dementia. However, the structural and cognitive correlates of insomnia are still not well understood. The study aims were to character...

    Authors: Oriol Grau-Rivera, Grégory Operto, Carles Falcón, Gonzalo Sánchez-Benavides, Raffaele Cacciaglia, Anna Brugulat-Serrat, Nina Gramunt, Gemma Salvadó, Marc Suárez-Calvet, Carolina Minguillon, Álex Iranzo, Juan Domingo Gispert and José Luis Molinuevo

    Citation: Alzheimer's Research & Therapy 2020 12:4

    Content type: Research

    Published on:

  14. Fluctuations are one of the core clinical features characterizing dementia with Lewy bodies (DLB). They represent a determining factor for its diagnosis and strongly impact the quality of life of patients and ...

    Authors: Eléna Chabran, Vincent Noblet, Paulo Loureiro de Sousa, Catherine Demuynck, Nathalie Philippi, Catherine Mutter, Pierre Anthony, Catherine Martin-Hunyadi, Benjamin Cretin and Frédéric Blanc

    Citation: Alzheimer's Research & Therapy 2020 12:9

    Content type: Research

    Published on:

  15. Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD). Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD pathology...

    Authors: Lisa Vermunt, Graciela Muniz-Terrera, Lea ter Meulen, Colin Veal, Kaj Blennow, Archie Campbell, Isabelle Carrié, Julien Delrieu, Karine Fauria, Gema Huesa Rodríguez, Silvia Ingala, Natalie Jenkins, José Luis Molinuevo, Pierre-Jean Ousset, David Porteous, Niels D. Prins…

    Citation: Alzheimer's Research & Therapy 2020 12:8

    Content type: Research

    Published on:

  16. Pathological processes contributing to Alzheimer’s disease begin decades prior to the onset of clinical symptoms. There is significant variation in cognitive changes in the presence of pathology, functional co...

    Authors: Chemin Lin, Maria Ly, Helmet T. Karim, Wenjing Wei, Beth E. Snitz, William E. Klunk and Howard J. Aizenstein

    Citation: Alzheimer's Research & Therapy 2020 12:7

    Content type: Research

    Published on:

  17. Although amyloid PET of typical Alzheimer’s disease (AD) shows diffuse ß-amyloid (Aß) deposition, some patients show focal deposition. The clinical significance of this focal Aß is not well understood. We exam...

    Authors: Si Eun Kim, Byungju Lee, Seongbeom Park, Soo Hyun Cho, Seung Joo Kim, Yeshin Kim, Hyemin Jang, Jee Hyang Jeong, Soo Jin Yoon, Kyung Won Park, Eun-Joo Kim, Na Yeon Jung, Bora Yoon, Jae-Won Jang, Jin Yong Hong, Jihye Hwang…

    Citation: Alzheimer's Research & Therapy 2020 12:6

    Content type: Research

    Published on:

  18. Alzheimer's disease (AD) is frequently accompanied by sleep impairment, which can induce AD-related neurodegeneration. We herein investigated the sleep architecture, cognition, and cerebrospinal fluid (CSF) bi...

    Authors: Claudio Liguori, Fabio Placidi, Francesca Izzi, Matteo Spanetta, Nicola Biagio Mercuri and Alessandra Di Pucchio

    Citation: Alzheimer's Research & Therapy 2020 12:5

    Content type: Research

    Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2020 12:53

  19. Plasma and cerebrospinal fluid levels of neurofilament light (NfL), a marker of axonal degeneration, have previously been reported to be raised in patients with clinically diagnosed Alzheimer’s disease (AD). A...

    Authors: Peter Parbo, Lasse Stensvig Madsen, Rola Ismail, Henrik Zetterberg, Kaj Blennow, Simon F. Eskildsen, Thomas Vorup-Jensen and David J. Brooks

    Citation: Alzheimer's Research & Therapy 2020 12:3

    Content type: Research

    Published on:

  20. In neurodegenerative dementias (NDs) such as prion disease, Alzheimer’s disease (AD), and frontotemporal lobar degeneration (FTLD), protein misfolding leads to the tissue deposition of protein aggregates which...

    Authors: Samir Abu-Rumeileh, Petra Steinacker, Barbara Polischi, Angela Mammana, Anna Bartoletti-Stella, Patrick Oeckl, Simone Baiardi, Corrado Zenesini, André Huss, Pietro Cortelli, Sabina Capellari, Markus Otto and Piero Parchi

    Citation: Alzheimer's Research & Therapy 2019 12:2

    Content type: Research

    Published on:

  21. Insulin impairment and inflammation are two features common to type 2 diabetes and Alzheimer’s disease; however, the molecular and signaling interactions underlying this relationship are not well understood. M...

    Authors: Maria Elizabeth De Sousa Rodrigues, Madelyn C. Houser, Douglas I. Walker, Dean P. Jones, Jianjun Chang, Christopher J. Barnum and Malú G. Tansey

    Citation: Alzheimer's Research & Therapy 2019 12:1

    Content type: Research

    Published on:

  22. The application of advanced sequencing technologies and improved mass-spectrometry platforms revealed significant changes in gene expression and lipids in Alzheimer’s disease (AD) brain. The results so far hav...

    Authors: Iliya Lefterov, Cody M. Wolfe, Nicholas F. Fitz, Kyong Nyon Nam, Florent Letronne, Richard J. Biedrzycki, Julia Kofler, Xianlin Han, Jianing Wang, Jonathan Schug and Radosveta Koldamova

    Citation: Alzheimer's Research & Therapy 2019 11:113

    Content type: Research

    Published on:

  23. Growing evidence suggests a role of occupation in the emergence and manifestation of dementia. Occupations are often defined by complexity level, although working environments and activities differ in several ...

    Authors: A. C. van Loenhoud, C. de Boer, K. Wols, Y. A. Pijnenburg, A. W. Lemstra, F. H. Bouwman, N. D. Prins, P. Scheltens, R. Ossenkoppele and W. M. van der Flier

    Citation: Alzheimer's Research & Therapy 2019 11:112

    Content type: Research

    Published on:

  24. Due to the high cost and high failure rate of ascertaining amyloid positron emission tomography positivity (PET+) in patients with earlier stage Alzheimer’s disease (AD), an effective pre-screening tool for am...

    Authors: Szu-Ying Lin, Kun-Ju Lin, Po-Chen Lin, Chin-Chang Huang, Chiung-Chih Chang, Yi-Chung Lee, Ing-Tsung Hsiao, Tzu-Chen Yen, Wen-Sheng Huang, Bang-Hung Yang and Pei-Ning Wang

    Citation: Alzheimer's Research & Therapy 2019 11:111

    Content type: Research

    Published on:

  25. The persistence of adult hippocampal neurogenesis (AHN) is sharply decreased in Alzheimer’s disease (AD). The neuropathologies of AD include the presence of amyloid-β deposition in plaques, tau hyperphosphoryl...

    Authors: Jaewoo Shin, Chanho Kong, Jihyeon Lee, Bo Young Choi, Jiyeon Sim, Chin Su Koh, Minkyung Park, Young Cheol Na, Sang Won Suh, Won Seok Chang and Jin Woo Chang

    Citation: Alzheimer's Research & Therapy 2019 11:110

    Content type: Research

    Published on:

  26. We examined interactive effects of sex, diagnosis, and cerebrospinal fluid (CSF) amyloid beta/phosphorylated tau ratio (Aβ/P-tau) on verbal memory and hippocampal volumes.

    Authors: Jessica Z. K. Caldwell, Jeffrey L. Cummings, Sarah J. Banks, Sebastian Palmqvist and Oskar Hansson

    Citation: Alzheimer's Research & Therapy 2019 11:109

    Content type: Research

    Published on:

  27. Cortical and subcortical cognitive impairments are usually found in dementia with Lewy bodies (DLB). Roughly, they comprise visuo-constructive/executive function and attention/processing speed impairments, whe...

    Authors: Anne Botzung, Nathalie Philippi, Vincent Noblet, Paulo Loureiro de Sousa and Frédéric Blanc

    Citation: Alzheimer's Research & Therapy 2019 11:108

    Content type: Research

    Published on:

  28. Alzheimer disease (AD) is characterized by the accumulation of beta-amyloid (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive ...

    Authors: Hayk Davtyan, Armine Hovakimyan, Sepideh Kiani Shabestari, Tatevik Antonyan, Morgan A. Coburn, Karen Zagorski, Gor Chailyan, Irina Petrushina, Olga Svystun, Emma Danhash, Nikolai Petrovsky, David H. Cribbs, Michael G. Agadjanyan, Mathew Blurton-Jones and Anahit Ghochikyan

    Citation: Alzheimer's Research & Therapy 2019 11:107

    Content type: Research

    Published on:

  29. Brain amyloid deposition is one of the main pathological characteristics of Alzheimer’s disease (AD). Soluble oligomers formed during the process that causes β-amyloid (Aβ) to aggregate into plaques are consid...

    Authors: Jian-Xiang Zhang, Yi-Hui Lai, Pan-Ying Mi, Xue-Ling Dai, Ran Zhang, Zhan-Jun Zhang, Shu-Juan Zhang, Xi-Wen Zhang, Xi-Yan Zhang, Bing-Yu Yang, Dong-Mei Cui, Chen Zhang, Chang-Qi Zhao and Fei Dou

    Citation: Alzheimer's Research & Therapy 2019 11:106

    Content type: Research

    Published on:

  30. Increased CSF levels of a number of synaptic markers have been reported in Alzheimer’s disease (AD), but little is known about their concentrations in frontotemporal dementia (FTD). We investigated this in thr...

    Authors: Mica T. M. Clarke, Ann Brinkmalm, Martha S. Foiani, Ione O. C. Woollacott, Carolin Heller, Amanda Heslegrave, Ashvini Keshavan, Nick C. Fox, Jonathan M. Schott, Jason D. Warren, Kaj Blennow, Henrik Zetterberg and Jonathan D. Rohrer

    Citation: Alzheimer's Research & Therapy 2019 11:105

    Content type: Research

    Published on:

  31. The control of viral infections in the brain involves the activation of microglial cells, the macrophages of the brain that are constantly surveying the central nervous system, and the production of amyloid-be...

    Authors: Daria Bortolotti, Valentina Gentili, Antonella Rotola, Elisabetta Caselli and Roberta Rizzo

    Citation: Alzheimer's Research & Therapy 2019 11:104

    Content type: Research

    Published on:

  32. Since both APOE and ABCA7 protein expression may independently reduce neuritic plaque burden and reorganize fibrillar amyloid burden-mediated disruption of functional connectivity in the default mode network, we ...

    Authors: Ya-Ting Chang, Shih-Wei Hsu, Shu-Hua Huang, Chi-Wei Huang, Wen-Neng Chang, Chia-Yi Lien, Jun-Jun Lee, Chen-Chang Lee and Chiung-Chih Chang

    Citation: Alzheimer's Research & Therapy 2019 11:103

    Content type: Research

    Published on:

  33. EphA4 is a receptor of the ephrin system regulating spine morphology and plasticity in the brain. These processes are pivotal in the pathophysiology of Alzheimer’s disease (AD), characterized by synapse dysfun...

    Authors: Lindsay Poppe, Laura Rué, Mieke Timmers, Annette Lenaerts, Annet Storm, Zsuzsanna Callaerts-Vegh, Gilles Courtand, Antina de Boer, Silke Smolders, Philip Van Damme, Ludo Van Den Bosch, Rudi D’Hooge, Bart De Strooper, Wim Robberecht and Robin Lemmens

    Citation: Alzheimer's Research & Therapy 2019 11:102

    Content type: Research

    Published on:

  34. We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor-mediated phagocytosis, in the SCarlet RoAD (SR...

    Authors: Gregory Klein, Paul Delmar, Nicola Voyle, Sunita Rehal, Carsten Hofmann, Danielle Abi-Saab, Mirjana Andjelkovic, Smiljana Ristic, Guoqiao Wang, Randall Bateman, Geoffrey A. Kerchner, Monika Baudler, Paulo Fontoura and Rachelle Doody

    Citation: Alzheimer's Research & Therapy 2019 11:101

    Content type: Research

    Published on:

  35. Amyloid-β PET and CSF Aβ42 yield discordant results in 10–20% of memory clinic patients, possibly providing unique information. Although the predictive power of demographic, clinical, genetic, and imaging feature...

    Authors: Juhan Reimand, Arno de Wilde, Charlotte E. Teunissen, Marissa Zwan, Albert D. Windhorst, Ronald Boellaard, Frederik Barkhof, Wiesje M. van der Flier, Philip Scheltens, Bart N. M. van Berckel, Rik Ossenkoppele and Femke Bouwman

    Citation: Alzheimer's Research & Therapy 2019 11:100

    Content type: Research

    Published on:

  36. Determination of β-amyloid (Aβ) positivity and likelihood of underlying Alzheimer’s disease (AD) relies on dichotomous biomarker cut-off values. Individuals with mild cognitive impairment (MCI) and Aβ within t...

    Authors: Anna Rosenberg, Alina Solomon, Vesna Jelic, Göran Hagman, Nenad Bogdanovic and Miia Kivipelto

    Citation: Alzheimer's Research & Therapy 2019 11:99

    Content type: Research

    Published on:

  37. Dementia has been presenting an imminent public health challenge worldwide. Studies have shown a combination of cognitive and physical trainings may have synergistic value for improving cognitive functions. Da...

    Authors: Lawla L. F. Law, Vincent C. T. Mok and Matthew M. K. Yau

    Citation: Alzheimer's Research & Therapy 2019 11:98

    Content type: Research

    Published on:

  38. Accumulation of amyloid β (Aβ) in the brain is proposed as a cause of Alzheimer’s disease (AD), with Aβ oligomers hypothesized to be the primary mediators of neurotoxicity. Crenezumab is a humanized immunoglob...

    Authors: William J. Meilandt, Janice A. Maloney, Jose Imperio, Guita Lalehzadeh, Tim Earr, Susan Crowell, Travis W. Bainbridge, Yanmei Lu, James A. Ernst, Reina N. Fuji and Jasvinder K. Atwal

    Citation: Alzheimer's Research & Therapy 2019 11:97

    Content type: Research

    Published on:

  39. To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association...

    Authors: Virginia Pérez-Grijalba, Javier Arbizu, Judith Romero, Elena Prieto, Pedro Pesini, Leticia Sarasa, Fernando Guillen, Inmaculada Monleón, Itziar San-José, Pablo Martínez-Lage, Josep Munuera, Isabel Hernández, Mar Buendía, Oscar Sotolongo-Grau, Montserrat Alegret, Agustín Ruiz…

    Citation: Alzheimer's Research & Therapy 2019 11:96

    Content type: Research

    Published on:

  40. The development of diagnostic tools capable of accurately identifying the pathophysiology of mild cognitive impairment (MCI) has become a crucial target considering the claim that disease-modifying treatments ...

    Authors: Alessandro Padovani, Alberto Benussi, Maria Sofia Cotelli, Clarissa Ferrari, Valentina Cantoni, Valentina Dell’Era, Rosanna Turrone, Barbara Paghera and Barbara Borroni

    Citation: Alzheimer's Research & Therapy 2019 11:95

    Content type: Research

    Published on:

  41. Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer’s disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and ne...

    Authors: Nicholas J. Ashton, Marc Suárez-Calvet, Amanda Heslegrave, Abdul Hye, Cristina Razquin, Pau Pastor, Raquel Sanchez-Valle, José L. Molinuevo, Pieter Jelle Visser, Kaj Blennow, Angela K. Hodges and Henrik Zetterberg

    Citation: Alzheimer's Research & Therapy 2019 11:94

    Content type: Research

    Published on:

  42. Metabolic alterations, related to cerebral glucose metabolism, brain insulin resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer’s disease (AD) on both the systemic and c...

    Authors: Vera van der Velpen, Tony Teav, Héctor Gallart-Ayala, Florence Mehl, Ioana Konz, Christopher Clark, Aikaterini Oikonomidi, Gwendoline Peyratout, Hugues Henry, Mauro Delorenzi, Julijana Ivanisevic and Julius Popp

    Citation: Alzheimer's Research & Therapy 2019 11:93

    Content type: Research

    Published on:

  43. Alzheimer’s disease (AD) clinical trials require enrollment of a participant and a study partner, whose role includes assessing participant cognitive and functional performance. AD trials now investigate early...

    Authors: Michelle M. Nuño, Daniel L. Gillen and Joshua D. Grill

    Citation: Alzheimer's Research & Therapy 2019 11:92

    Content type: Research

    Published on:

  44. Ongoing efforts within the Alzheimer’s disease (AD) field have focused on improving the intra- and inter-laboratory variability for cerebrospinal fluid (CSF) biomarkers. Fully automated assays offer the possib...

    Authors: Maria João Leitão, Anuschka Silva-Spínola, Isabel Santana, Veronica Olmedo, Alicia Nadal, Nathalie Le Bastard and Inês Baldeiras

    Citation: Alzheimer's Research & Therapy 2019 11:91

    Content type: Research

    Published on:

  45. It has been claimed that the retina can be used as a window to study brain disorders. However, concerning Alzheimer’s disease (AD), it still remains controversial whether changes occurring in the brain and ret...

    Authors: Samuel Chiquita, Elisa J. Campos, João Castelhano, Mário Ribeiro, José Sereno, Paula I. Moreira, Miguel Castelo-Branco and António Francisco Ambrósio

    Citation: Alzheimer's Research & Therapy 2019 11:90

    Content type: Research

    Published on:

  46. The objectives of this study were to investigate whether the plasma levels of oligomeric amyloid-β (OAβ) were affected in Alzheimer’s disease (AD) and to examine the associations (or possible correlations) bet...

    Authors: Xue Meng, Tao Li, Xiao Wang, Xiaozhen Lv, Zhiyu Sun, Jichun Zhang, Feng Su, Sungmin Kang, SangYun Kim, Seong Soo A. An, Xin Yu, Chen Zhang and Huali Wang

    Citation: Alzheimer's Research & Therapy 2019 11:89

    Content type: Research

    Published on:

  47. Loss-of-function mutations in the progranulin gene cause frontotemporal dementia, a genetic, heterogeneous neurodegenerative disorder. Progranulin deficiency leads to extensive neuronal loss in the frontal and...

    Authors: Dávid Nagy, Lauren Herl Martens, Liza Leventhal, Angela Chen, Craig Kelley, Milan Stoiljkovic and Mihály Hajós

    Citation: Alzheimer's Research & Therapy 2019 11:88

    Content type: Research

    Published on:

  48. Physical activity might reduce the risk of developing dementia. However, it is still unclear whether the protective effect differs depending on the subtype of dementia. We aimed to investigate if midlife physi...

    Authors: Oskar Hansson, Martina Svensson, Anna-Märta Gustavsson, Emelie Andersson, Yiyi Yang, Katarina Nägga, Ulf Hållmarker, Stefan James and Tomas Deierborg

    Citation: Alzheimer's Research & Therapy 2019 11:87

    Content type: Research

    Published on:

  49. Preclinical Alzheimer’s disease (AD) clinical trials require participants to enroll with a study partner, a person who can attend visits and report changes in the participant’s cognitive ability. Whether study...

    Authors: Mary M. Ryan, Joshua D. Grill and Daniel L. Gillen

    Citation: Alzheimer's Research & Therapy 2019 11:85

    Content type: Research

    Published on: